March 21, 2019 07:13 AM EDTUpdated 02:05 PM

Biogen's Alzheimer's drug aducanumab implodes in a PhIII disaster — putting them at a perilous crossroads

John Carroll

Editor & Founder

Biogen’s big late-stage play in Alzheimer’s has just crashed. And the damage will be extensive.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

Biogen's Alzheimer's drug aducanumab implodes in a PhIII disaster — putting them at a perilous crossroads

John Carroll

Editor & Founder

Unlock this article instantly by becoming a free subscriber.

FDA rolls out long-awaited proposal to overhaul diagnostics regulation

FDA unveils new rare disease pilot program to increase agency-sponsor communications

In the race to get type 1 patients off insulin, focus turns to cell transplants and insulin-producing stem cells

Exclusive: Former Genentech duo reunites to push Sonoma into the clinic; Ex-Magenta commercial chief heads to Editas

Madrigal raises $500M for NASH drug launch, discloses cyberattack

Data Quality 2.0: The Future of Real-World Evidence

Bio­gen's Alzheimer's drug ad­u­canum­ab im­plodes in a PhI­II dis­as­ter — putting them at a per­ilous cross­roads

John Carroll

Editor & Founder

Unlock this article instantly by becoming a free subscriber.

FDA rolls out long-await­ed pro­pos­al to over­haul di­ag­nos­tics reg­u­la­tion

FDA un­veils new rare dis­ease pi­lot pro­gram to in­crease agency-spon­sor com­mu­ni­ca­tions

In the race to get type 1 pa­tients off in­sulin, fo­cus turns to cell trans­plants and in­sulin-pro­duc­ing stem cells

Ex­clu­sive: For­mer Genen­tech duo re­unites to push Sono­ma in­to the clin­ic; Ex-Ma­gen­ta com­mer­cial chief heads to Ed­i­tas

Madri­gal rais­es $500M for NASH drug launch, dis­clos­es cy­ber­at­tack

Da­ta Qual­i­ty 2.0: The Fu­ture of Re­al-World Ev­i­dence

Biogen's Alzheimer's drug aducanumab implodes in a PhIII disaster — putting them at a perilous crossroads

FDA rolls out long-awaited proposal to overhaul diagnostics regulation

FDA unveils new rare disease pilot program to increase agency-sponsor communications

In the race to get type 1 patients off insulin, focus turns to cell transplants and insulin-producing stem cells

Exclusive: Former Genentech duo reunites to push Sonoma into the clinic; Ex-Magenta commercial chief heads to Editas

Madrigal raises $500M for NASH drug launch, discloses cyberattack

Data Quality 2.0: The Future of Real-World Evidence